

**DAY 3**

**Saturday, March 7, 2020**

**E** : English **EL** : Educational Lecture  
**BS** : Breakfast Seminar **LS** : Luncheon Seminar

		7:30	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
Hall Building	Room1 4F Hall C			9:00~11:00 <b>Symposium 3</b> How to select GVHD prophylaxis in haplo-identical transplantation Toshihiro Miyamoto, Masayuki Hino P.11			11:25~12:15 <b>LS12</b> Evidence and practice of CAR-T cell therapy in r/r B-cell malignancies Speaker: Yoshinobu Maeda Chair: Takanori Teshima Tomoko Yashima (Novartis Pharma K.K.)	12:30~13:00 JSHCT Prize Commemorative Lecture P.11	13:10~13:55 <b>Plenary Session</b> Junji Tanaka P.12	14:00~14:45 <b>Special Lecture</b> Speaker: Takanori Teshima Chair: Mine Harada P.12	14:50~16:00 <b>Symposium 4</b> Management of post-cell therapy cytokine storm Yoshinobu Kanda, Naoyuki Uchida P.13						
	Room2 7F Hall B7 (1)	8:00~8:50 <b>BS1</b> Treatment strategy for transplant eligible multiple myeloma 2020 Speaker: Nobuhiro Tsukada Chair: Toshihiro Miyamoto (Takeda Pharmaceutical Company Limited)		9:00~11:00 <b>Nursing Symposium</b> Chieko Indo, Mihoko Mahara P.13			11:25~12:15 <b>LS13</b> Treatment Strategies for Multiple Myeloma -The role of IMiDs- Speaker: Hiroshi Handa Chair: Shinsuke Iida (Celgene KK.)	13:20~14:00 <b>Oral Session for Nurse 3</b> Nursing Education Tomomi Mochizuki Mayumi Tsukagoshi P.82	14:05~15:05 <b>Team Approach 1</b> Takako Arai P.14	15:10~16:10 <b>Team Approach 2</b> Reiko Yamahana P.14							
	Room3 7F Hall B7 (2)	8:00~8:50 <b>BS2</b> The impact of immune checkpoint inhibitors on the clinical outcome of allogeneic hematopoietic stem cell transplantation Speaker: Koji Kato Chair: Takanori Teshima (ONO PHARMACEUTICAL CO.,LTD./ Bristol-Myers Squibb KK.)		9:00~10:15 <b>Workshop 3</b> Susumu Ohmae, Noriko Doki P.15	10:15~11:15 <b>Special Planning 2</b> Shuichi Taniguchi P.15		11:25~12:15 <b>LS14</b> The Recent Transition of the AML Management Speaker: Toshihiro Miyamoto Chair: Mine Harada (DAIICHI SANKYO CO., LTD.)	13:05~13:40 <b>Current Seminar 3</b> Takanori Teshima P.16	13:45~14:15 <b>Current Seminar 4</b> Kenshi Suzuki P.16	14:20~16:00 <b>Workshop 4</b> Takahiro Fukuda, Yuki Mori P.16							
	Room4 5F Hall B5	8:00~8:50 <b>BS3</b> Treatment strategy for Ph-positive ALL Speaker: Tadakazu Kondoh Clinical risks and benefits of positron in the treatment of Ph-leukemia Speaker: Takeshi Kondo Chair: Makoto Murata (Otsuka Pharmaceutical Co.,LTD.)		9:00~10:00 <b>JDCHCT/ National Survey News</b>	10:05~10:35 <b>Educational Seminar ⑦</b>	10:40~11:10 <b>Educational Seminar ⑧</b>	11:25~12:15 <b>LS15</b> Treatment Strategies for PTCL Speaker: Choji Iseiyung Chair: Kenji Ishitsuka (Takeda Pharmaceutical Company Limited)	12:25~13:15 <b>Nursing Group Meeting</b>		13:50~14:20 <b>EL9</b> Speaker: Yoshinobu Kanda Chair: Tetsuo Ichinohe P.17	14:25~14:55 <b>EL10</b> Speaker: Yoshiko Atsuta Chair: Satoshi Takahashi P.17	15:00~15:30 <b>Educational Seminar ⑨</b>	15:35~16:05 <b>Educational Seminar ⑩</b>				
	Room5 7F Hall D7	8:00~8:50 <b>E</b> <b>BS4</b> Allogeneic Stem Cell Transplantation in MDS Speaker: Thomas Schroeder Chair: Shinichiro Okamoto (NIPPON SHINYAKU CO.,LTD.)		9:00~10:40 <b>E</b> <b>JSHCT-KSBMT Joint Symposium</b> Post-transplant complication Shinichiro Okamoto, Kook Hoon P.17			11:25~12:15 <b>LS16</b> The role of allogeneic hematopoietic stem cell transplantation and anti-CD19 therapy in B-cell lymphomas Speaker: Kim Sung-Won Chair: Takayuki Ishikawa (MSD K.K.)		14:00~16:00 <b>Public Forum</b>								
	Room6 5F Hall D5	8:00~8:50 <b>BS5</b> Latest treatment strategy and future outlook in Adult Aplastic Anemia Speaker: Hisashi Yamamoto Ken Ishiyama Chair: Tetsuya Eto (Novartis Pharma K.K.)		9:00~10:00 <b>Oral Session 28</b> Transplant Outcomes (Non-remission) Yuta Katayama P.49	10:10~10:58 <b>Oral Session 29</b> Transplant Outcomes (Non-remission/ Multiple Transplants) Seiko Kato P.50		11:25~12:15 <b>E</b> <b>LS17</b> Past, present and future role of Blinatumomab for treatment of Acute Lymphoblastic Leukemia Speaker: Anthony S. Stein Chair: Junji Tanaka (Amgen Astellas BioPharma K.K./ Astellas Pharma)		13:50~14:50 <b>Oral Session 30</b> Minimal Residual Disease and Recurrence Tomonori Kato P.51	15:00~16:00 <b>Oral Session 31</b> Transplant Outcomes (Geriatrics) Noriaki Kawano P.52							
	Room7 1F Hall D1	8:00~8:50 <b>BS6</b> Future Developments in the Treatment of Acute Lymphoblastic Leukemia: Improvement of Treatment Outcomes by Risk Stratification Speaker: Katsuyoshi Koh Chair: Keizo Horibe (Amgen Astellas BioPharma K.K.)		9:00~9:48 <b>Oral Session 32</b> Late Complication 1 Masatoshi Sakurai P.53	10:00~10:48 <b>Oral Session 33</b> Late Complication 2 Nobuhiko Imahashi P.54		11:25~12:15 <b>LS18</b> Follicular lymphoma up-to-date Speaker: Koji Izutsu Chair: Shingo Yano (Eisai Co., Ltd./ Symbio Pharmaceuticals Limited)		13:50~14:50 <b>E</b> <b>Oral Session 34</b> MM/Plasma cell disease 1 Hiroyuki Takamatsu P.55	15:00~16:12 <b>Oral Session 35</b> MM/Plasma cell disease 2 Kenjiro Kamezaki P.57							
Glass Building	Room8 5F G502		9:00~10:00 <b>Oral Session 36</b> Lymphoma/ ATL 1 Takashi Ikeda P.58	10:10~10:58 <b>Oral Session 37</b> Lymphoma/ ATL 2 Tomonori Nakazato P.59		11:25~12:15 <b>LS19</b> Flow-MRD adapted strategy for the treatment of multiple myeloma Speaker: Kenshi Suzuki Chair: Shigeki Ito (Nippon Becton Dickinson Company, Ltd.)	12:25~13:25 <b>HCTC Group Meeting</b>	13:50~15:02 <b>Oral Session 38</b> Lymphoma/ ATL 3 Yuho Najima P.60	15:10~16:22 <b>Oral Session 39</b> Lymphoma/ ATL 4 Masaharu Nougawa P.62								
	Room9 5F G510		9:00~10:00 <b>Oral Session 40</b> Transplant Outcomes (ALL) Tetsuo Maeda P.64	10:10~11:10 <b>Oral Session 41</b> Transplant Outcomes (Ph-positive Leukemia) Hiroshi Matsuoka P.65		11:25~12:15 <b>LS20</b> A discussion of fungal infections between hematologic and infectious disease doctor Speaker: Yuki Mori Hirotaki Arai Chair: Shinichiro Okamoto (Pfizer Japan Inc.)	12:25~13:25 <b>HCTC Group Meeting</b>	13:50~14:50 <b>Oral Session 42</b> Transplant Outcomes (AML/ MDS) Shio Mitsukawa P.66	15:00~15:48 <b>Oral Session 43</b> Transplant Outcomes (MDS/ MPN) Yasunobi Sekiguchi P.67								
	Room10 4F G402		9:00~10:00 <b>Oral Session 44</b> Transplant Outcomes (Pediatrics) 1 Kumiko Goi P.68	10:10~10:58 <b>Oral Session 45</b> Transplant Outcomes (Pediatrics) 2 Asahito Hama P.69		11:25~12:15 <b>LS21</b> The frontline therapy for PNH ~Next step of terminal complement therapy~ Speaker: Takayuki Ikezoe Chair: Shinji Nakao (Alexion Pharma GK)		13:50~14:50 <b>Oral Session 46</b> Child-specific Transplant Disease Hiroaki Goto P.70	15:00~16:00 <b>Oral Session 47</b> Stem Cell Mobilization and Collection Toshihiko Ando P.71								
	Room11 4F G409		9:00~10:00 <b>Oral Session 48</b> Transplant Outcomes (Others) 1 Takafumi Yokota P.72	10:10~10:58 <b>Oral Session 49</b> Transplant Outcomes (Others) 2 Hiroki Yokoyama P.73		11:25~12:15 <b>LS22</b> Pre and post-transplant results in patients with Philadelphia chromosome-positive leukemia Speaker: Shigeo Fujii Presenting experience after BSCT Speaker: Kazuhiro Ikegami Chair: Makoto Onizuka (Otsuka Pharmaceutical Co.,LTD.)		13:50~15:02 <b>Oral Session 50</b> Bacterial Infection Satoshi Yoshihara P.74	15:10~16:10 <b>Oral Session 51</b> Fungal Infection/ Other Infection Hiroki Yamaguchi P.75								
	Room12 6F G602		9:00~10:00 <b>Oral Session 52</b> Hematopoietic Cell Transplant Coordinator and Coordination 1 Madoka Narita P.76	10:10~11:10 <b>Oral Session 53</b> Hematopoietic Cell Transplant Coordinator and Coordination 2 Mariko Kawaguchi P.77		11:25~12:15 <b>LS23</b> Current status of CAR-T therapy Speaker: Koji Kato Chair: Hideo Harigae (Japan Blood Products Organization)		13:50~14:50 <b>Oral Session 54</b> Oral Care Sumiko Kohashi P.78	15:00~15:48 <b>Oral Session 55</b> Marrow Donor Program/ Cord Blood Bank/ Donors Takaaki Konuma P.79								
Hall E	Poster B2F	8:00~9:00 Poster mounting	9:00~16:15 Poster viewing		16:15~17:00 Poster Presentation P.83							17:10~17:30 Poster removal					
	Exhibition B2F		9:00~17:00 Exhibition														

**Poster Presentation**

002~P-008 Stem Cell Mobilization and Collection  
P-010~P-014 Transplant Source  
P-016~P-024 Conditioning  
P-026~P-048 Transplant Immunity  
P-050~P-052 Immunotherapy/Cell Therapy  
P-054~P-056 Child-specific Transplant Disease  
P-058~P-100 Transplant Outcomes  
P-102~P-116 Malignant Lymphoma/ATL  
P-118~P-134 Minimal Residual Disease and Recurrence  
P-136~P-144 Early Complication  
P-146~P-182 Late Complication  
P-184~P-192 Bacterial Infection  
P-194~P-214 Viral Infection  
P-216~P-228 Fungal Infection/Other Infection  
P-230~P-232 LTFU/QOL  
P-234 Marrow Donor Program/Cord Blood Bank/Donors  
P-236~P-238 Hematopoietic Cell Transplant Coordinator and Coordinate  
P-240~P-250 Management/Care/Team Medical-care  
P-252~P-268 Rehabilitation  
P-270~P-274 TDM/Drugs

**Nursing Poster Presentation**

NurseP2-01~P2-08 Care  
NurseP2-09~P2-12 Infection control  
NurseP2-13~P2-18 Follow-up  
NurseP2-19~P2-22 Decision support  
NurseP2-23~P2-25 Team approach  
NurseP2-26~P2-32 Nursing Management, Education